| Company | Date | Position | Consensus β | Price Target β | 1-Yr Return | vs S&P 500 β |
|---|---|---|---|---|---|---|
|
MDGL
Madrigal Pharmaceuticals
|
Oct 16, 2026 | BUY |
Strong Buy
+20.2% avg upside
34 analysts
|
$685.00
59.12% Upside
|
-11.1% | Β· |
|
DNTH
Dianthus Therapeutics
|
Oct 16, 2026 | BUY |
Strong Buy
+23.4% avg upside
32 analysts
|
$135.00
63.94% Upside
|
+15.2% | Β· |
|
MAZE
Maze Therapeutics, Inc.
|
Oct 15, 2026 | BUY |
Strong Buy
+102.8% avg upside
14 analysts
|
$55.00
74.66% Upside
|
+18.4% | Β· |
|
VOR
Vor Biopharma
|
Aug 31, 2026 | BUY |
Strong Buy
+117.7% avg upside
19 analysts
|
$30.00
52.42% Upside
|
-17.0% | Β· |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.